Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Carrington Laboratories has signed multi-year supply and patent license agreements with Primus Pharmaceuticals relating to the manufacture of products with acemannan hydrogel.
Subscribe to our email newsletter
Under the terms of the royalty bearing agreements, Carrington will supply its raw material, acemannan hydrogel, to Primus for use in topical prescription products. In exchange for guaranteed royalties on sales of these products, Primus will receive patent and marketing protection under relevant Carrington patents that cover process, composition of matter and use.
“We feel Primus’s business model is in line with our goals and will help us to diversify our brand in the medical market,” stated Doug Golwas, vice president of corporate sales and marketing for Carrington.
Primus markets prescription metabolic products throughout the US. Its products Alcortin and Novacort will contain acemannan hydrogel and are used as treatments for a wide range of dermatological infections and inflammatory conditions.